NEW YORK--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQX: CBSTF) (FSE: 3LP) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today it is launching the brand dreamt, in Maryland, with additional markets and products to follow in 2025. Earlier this year, the Company acquired the brand through its acquisition of the Ciencia Labs portfolio.
The dreamt brand stands out from other cannabis products because of its unique formulations, which include a precise ratio of THC to CBD, in addition to a variety of supplements including GABA, and valerian root.
“dreamt is a transformative product, and we couldn’t be more excited to bring these highly sought after products to our shelves. Everyone deserves a good night's sleep to feel refreshed and be at their best,” said Jesse Channon, President, The Cannabist Company. “dreamt products will utilize our high-quality cannabis to make a positive impact in people’s daily lives, as we strive to bring innovation and excellence to our markets.”
“dreamt is the result of extensive formulation development. Our goal was to produce these products at our state-of-the-art facilities across multiple markets and provide our patients and customers with a consistent and reliable experience,” said Blake Brower, VP, National Operations, The Cannabist Company. “We’re proud of our ability to maximize our facility's capabilities and supply these high-quality products in the most demanded product category.”
dreamt is now available as a 5mg THC, 2mg CBD, 1mg CBN gummy sold in a 20 pack, at Columbia Care Chevy Chase and gLeaf dispensaries in Maryland and across the Company’s wholesale channels. The brand will debut in additional markets and expand its product offering in 2025.
For more information, visit cannabistcompany.com or youdreamt.com.
About The Cannabist Company (f/k/a Columbia Care)
The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 14 U.S. jurisdictions. The Company operates 91 facilities including 71 dispensaries and 20 cultivation and manufacturing facilities, including those under development and assuming the closure of announced divesture transactions. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit www.cannabistcompany.com.
Caution Concerning Forward-Looking Statements
This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company’s ability to execute on retail, wholesale, brand and product initiatives. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. In addition, security holders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10-K for the year ended December 31, 2023, as filed with Canadian and U.S. securities regulatory authorities and described from time to time in subsequent documents filed with applicable securities regulatory authorities.
